As inhibiting CSF-1R could block the CSF-1/CSF-1R signaling pathway, which is responsible for macrophage differentiation and proliferation, re-education of TAMs could lead to therapeutic therapy for advanced tumors.308,309 The FDA approved PLX3397 (pexidartinib), a CSF-1R inhibitor, in 2019 as the first and only drug to target CSF-1R for the treatment of malignant fibrous histiocytoma (TGCT), with more drugs being in clinical trials. The gene discussed is CSF1R; the disease is undifferentiated pleomorphic sarcoma.